CN115141763A - 一株高效外泌蛋白的酵母工程菌及其构建方法和应用 - Google Patents
一株高效外泌蛋白的酵母工程菌及其构建方法和应用 Download PDFInfo
- Publication number
- CN115141763A CN115141763A CN202210642012.9A CN202210642012A CN115141763A CN 115141763 A CN115141763 A CN 115141763A CN 202210642012 A CN202210642012 A CN 202210642012A CN 115141763 A CN115141763 A CN 115141763A
- Authority
- CN
- China
- Prior art keywords
- yeast
- gene
- sec72
- genetically engineered
- recombinant protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 40
- 241000894006 Bacteria Species 0.000 title claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 title abstract description 32
- 230000003248 secreting effect Effects 0.000 title abstract description 15
- 238000010276 construction Methods 0.000 title abstract description 12
- 238000001814 protein method Methods 0.000 title description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 69
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 43
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 36
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 36
- 101150017402 sec72 gene Proteins 0.000 claims abstract description 33
- 230000028327 secretion Effects 0.000 claims abstract description 29
- 239000013613 expression plasmid Substances 0.000 claims abstract description 13
- 238000010353 genetic engineering Methods 0.000 claims abstract description 11
- 101100186604 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NCW2 gene Proteins 0.000 claims abstract description 7
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 claims abstract description 7
- 101100422775 Arabidopsis thaliana SUP gene Proteins 0.000 claims abstract description 6
- 102100039216 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 Human genes 0.000 claims abstract description 6
- 101150073536 FET3 gene Proteins 0.000 claims abstract description 6
- 101000670093 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 Proteins 0.000 claims abstract description 6
- 101000766246 Homo sapiens Probable E3 ubiquitin-protein ligase MID2 Proteins 0.000 claims abstract description 6
- 102100026310 Probable E3 ubiquitin-protein ligase MID2 Human genes 0.000 claims abstract description 6
- 101100066906 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FLO10 gene Proteins 0.000 claims abstract description 6
- 101150032817 TPI1 gene Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 108090000637 alpha-Amylases Proteins 0.000 claims description 8
- 102000004139 alpha-Amylases Human genes 0.000 claims description 7
- 229940024171 alpha-amylase Drugs 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 4
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 claims description 3
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 claims description 3
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 2
- 108010059892 Cellulase Proteins 0.000 claims description 2
- 101500025915 Homo sapiens Angiostatin Proteins 0.000 claims description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 108010059881 Lactase Proteins 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 108700040099 Xylose isomerases Proteins 0.000 claims description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108010019077 beta-Amylase Proteins 0.000 claims description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 2
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 2
- 229940106157 cellulase Drugs 0.000 claims description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 2
- 239000001573 invertase Substances 0.000 claims description 2
- 235000011073 invertase Nutrition 0.000 claims description 2
- 229940116108 lactase Drugs 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 abstract description 7
- 108010006519 Molecular Chaperones Proteins 0.000 abstract description 5
- 102000005431 Molecular Chaperones Human genes 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000008685 targeting Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000008439 repair process Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 8
- 238000001502 gel electrophoresis Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- 101000801742 Homo sapiens Triosephosphate isomerase Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001976 enzyme digestion Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 108020005004 Guide RNA Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108010065511 Amylases Proteins 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000352457 Shivajiella indica Species 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000003209 gene knockout Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- OMFMCIVBKCEMAK-CYDGBPFRSA-N Ala-Leu-Val-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O OMFMCIVBKCEMAK-CYDGBPFRSA-N 0.000 description 1
- DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 1
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 1
- XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 1
- XWKBWZXGNXTDKY-ZKWXMUAHSA-N Asp-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O XWKBWZXGNXTDKY-ZKWXMUAHSA-N 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- VFGADOJXRLWTBU-JBDRJPRFSA-N Cys-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N VFGADOJXRLWTBU-JBDRJPRFSA-N 0.000 description 1
- SRZZZTMJARUVPI-JBDRJPRFSA-N Cys-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N SRZZZTMJARUVPI-JBDRJPRFSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 1
- TZCGZYWNIDZZMR-NAKRPEOUSA-N Ile-Arg-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)O)N TZCGZYWNIDZZMR-NAKRPEOUSA-N 0.000 description 1
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 1
- UAQSZXGJGLHMNV-XEGUGMAKSA-N Ile-Gly-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N UAQSZXGJGLHMNV-XEGUGMAKSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 description 1
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 1
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
- OBVHKUFUDCPZDW-JYJNAYRXSA-N Met-Arg-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OBVHKUFUDCPZDW-JYJNAYRXSA-N 0.000 description 1
- GPVLSVCBKUCEBI-KKUMJFAQSA-N Met-Gln-Phe Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GPVLSVCBKUCEBI-KKUMJFAQSA-N 0.000 description 1
- UNPGTBHYKJOCCZ-DCAQKATOSA-N Met-Lys-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O UNPGTBHYKJOCCZ-DCAQKATOSA-N 0.000 description 1
- BJPQKNHZHUCQNQ-SRVKXCTJSA-N Met-Pro-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCSC)N BJPQKNHZHUCQNQ-SRVKXCTJSA-N 0.000 description 1
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- WKTSCAXSYITIJJ-PCBIJLKTSA-N Phe-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O WKTSCAXSYITIJJ-PCBIJLKTSA-N 0.000 description 1
- XZQYIJALMGEUJD-OEAJRASXSA-N Phe-Lys-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZQYIJALMGEUJD-OEAJRASXSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- GMWNQSGWWGKTSF-LFSVMHDDSA-N Phe-Thr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMWNQSGWWGKTSF-LFSVMHDDSA-N 0.000 description 1
- ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 description 1
- VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 description 1
- NHQVWACSJZJCGJ-FLBSBUHZSA-N Thr-Thr-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NHQVWACSJZJCGJ-FLBSBUHZSA-N 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 101710194411 Triosephosphate isomerase 1 Proteins 0.000 description 1
- AZZLDIDWPZLCCW-ZEWNOJEFSA-N Tyr-Ile-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O AZZLDIDWPZLCCW-ZEWNOJEFSA-N 0.000 description 1
- PVPAOIGJYHVWBT-KKHAAJSZSA-N Val-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N)O PVPAOIGJYHVWBT-KKHAAJSZSA-N 0.000 description 1
- ZZGPVSZDZQRJQY-ULQDDVLXSA-N Val-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O ZZGPVSZDZQRJQY-ULQDDVLXSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010087049 alanyl-alanyl-prolyl-valine Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2414—Alpha-amylase (3.2.1.1.)
- C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
- C12N9/242—Fungal source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/85—Saccharomyces
- C12R2001/865—Saccharomyces cerevisiae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一株高效外泌蛋白的酵母工程菌及其构建方法和应用,该酵母基因工程菌是敲除酵母菌株中的SEC72基因后得到的;所述的酵母基因工程菌还含有携带信号肽的重组蛋白分泌表达质粒;所述信号肽是NCW2、MID2、SWP1、FET3、FLO10或α‑factor中的一种。本发明构建了一株高效外泌蛋白的酿酒酵母工程菌,可使多种信号肽介导重组蛋白分泌的产量得到明显提高。该酵母基因工程菌针对介导分泌相关的分子伴侣复合体进行改造,蛋白分泌能力提升对于多种信号肽具有普适性,为高效分泌表达目标蛋白提供奠定了基础。该酵母基因工程菌在重组蛋白分泌生产上展现出较大的应用潜力。
Description
技术领域
本发明涉及一株高效外泌蛋白的酵母工程菌及其构建方法和应用,属于微生物及基因工程领域。
背景技术
酿酒酵母是单细胞真核生物,兼具真核生物及微生物的优势。其生长繁殖快、易于进行基因工程改造、能进行蛋白翻译后修饰、具有较强环境耐受性及底物利用谱广等特点,已被广泛地应用在重组蛋白工业生产上。如胰岛素、病毒疫苗生产等。基于酿酒酵母应用的普适性,对酿酒酵母的基因信息和蛋白质表达等展开了大量研究,如酿酒酵母是首个实现基因组测序的真核生物,其多年前便用于胰岛素的生产。目前,全球近一半的胰岛素仍以酿酒酵母为生产平台进行供应。
利用真核生物进行重组蛋白制备时,宿主细胞以分泌形式进行蛋白表达是较受欢迎的一种方式。因为这可促使目标蛋白在经过分泌途径而外泌至胞外的过程中,得到适当的翻译后修饰,保证重组蛋白具有生理活性。同时,外泌至胞外的重组蛋白也有利于进行下游纯化,极大地减轻了纯化环节的压力,有利于提升经济效益。目前,对于重组蛋白在酵母中的分泌表达,通常在目标蛋白的N端添加信号肽来实现介导分泌。尽管添加信号肽可实现外源蛋白的分泌,然而,部分外源蛋白在酵母系统中表达时分泌效率较低,这会限制酵母在大规模生产上的应用。通过基因改造手段,可以提升酵母的重组蛋白分泌能力。但目前很多改造的靶点,提升幅度较小,且有时只对特定的信号肽有效,导致适用性较为有限。目前在改造靶点及手段上,都有待进一步拓展完善。
发明内容
本发明的目的在于提供一株高效外泌蛋白的酵母工程菌及其构建方法和应用,来解决现有改造靶点提升幅度小、对不同信号肽的普适性较窄的不足。本发明针对与介导分泌相关的分子伴侣复合体上的一个蛋白Sec72进行敲除,克服了现有技术的缺陷,实现了多种信号肽在酵母中介导蛋白分泌的能力都得到了较大提升。
本发明的目的通过下述技术方案实现:
一株酵母基因工程菌,是敲除酵母菌株中的SEC72基因后得到;
所述SEC72基因的序列如SEQ ID NO:2所示;
SEC72基因编码的Sec72蛋白,是介导分泌转运相关的一种分子伴侣复合体上的亚基之一;该分子伴侣复合体为内质网上的转运通道,可通过识别新生蛋白质的信号肽序列,将新生蛋白质从胞质中介导转运至内质网中,随后新生蛋白质可在内质网中继续完成蛋白分泌后续步骤。Sec72蛋白参与信号肽序列识别过程。基于本发明,发现对其进行改造(敲除),有助于完成新生蛋白质的内质网转运,从而提升了蛋白外泌的效率。
所述的酵母菌株优选酿酒酵母IMX581、CEN.PK2-1C、CEN.PK2-1D、BY4741、BY4742、CEN.PK 530.1C、CEN.PK 113.5D、B184M。
所述的酵母基因工程菌还含有携带信号肽的重组蛋白分泌表达质粒;
所述信号肽可以是NCW2、MID2、SWP1、FET3、FLO10或α-factor中的一种;
所述的重组蛋白可以是α-淀粉酶、脂肪酶、β-淀粉酶、蛋白酶、乳糖酶、α-葡萄糖苷酶、葡糖异构酶、转化酶、纤维素酶、纤维二糖酶、人血清白蛋白、病毒表面抗原、人胰岛素、人粒细胞集落刺激因子、人血管抑制素、抗体等。
优选地,所述的重组蛋白分泌表达质粒带有POT1筛选标记;这种情况下,还应当敲除酵母菌株中的TPI1基因,使重组蛋白分泌表达质粒在酵母菌稳定存在;
所述TPI1基因的序列如SEQ ID NO:1所示。
上述酵母基因工程菌的构建方法,包括以下步骤:
敲除酵母菌株上的SEC72基因,构建携带信号肽的重组蛋白分泌表达质粒,将携带信号肽的重组蛋白分泌表达质粒转化至敲除SEC72基因的酵母菌株中,得到所述酵母基因工程菌。
上述的酵母基因工程菌在表达重组蛋白中的应用;将上述酵母基因工程菌接种于发酵培养基中进行发酵培养,收集发酵培养产物即可得相应的重组蛋白。
本发明相对于现有技术具有如下的优点及效果:
本发明构建了一株高效外泌蛋白的酿酒酵母工程菌,可使包括NCW2、MID2、SWP1、FET3、FLO10和α-factor等在内的多种信号肽介导重组蛋白分泌的产量得到明显提高(1.7~2.5倍)。该酵母基因工程菌针对介导分泌相关的分子伴侣复合体进行改造,蛋白分泌能力提升对于多种信号肽具有普适性,为高效分泌表达目标蛋白提供奠定了基础。该酵母基因工程菌在重组蛋白分泌生产上展现出较大的应用潜力。
附图说明
图1为PCR扩增pROS10载体框架,TPI1靶向片段A和SEC72靶向片段B的凝胶电泳条带图。
图2为TPI1修复片段A和SEC72修复片段B的凝胶电泳条带图。
图3为TPI1基因敲除验证片段A和SEC72敲除验证片段B的凝胶电泳条带图。
图4为带不同信号肽的分泌表达α-淀粉酶的质粒示意图。
图5为pAlphaAmyCPOT酶切条带凝胶电泳图。
图6为对照菌株S1和改造菌株S1ΔSEC72的分泌生产淀粉酶的产量。
具体实施方式
下面结合实施例及附图对本发明作进一步详细的描述,但本发明的实施方式不限于此。
下述实施例中所用的PCR试剂、限制性内切酶、质粒抽提试剂盒、DNA胶回收试剂盒等采用商业产品多已注明商业来源,具体操作按照试剂盒说明书进行。
下列实施例中未注明具体条件的实验方法,则通常按照常规条件,如《分子克隆实验指南》(北京:科学出版社,2017)、《酵母遗传学方法实验指南》(北京:科学出版社,2016)中所述的条件进行。
下述实施例中应用到的CRISPR技术参见现有技术(FEMS Yeast Research,2015,15(2):fov004.)。
为更好地理解本发明的内容,以酿酒酵母(Saccharomyces cerevisiae)IMX581(可由EUROSCARF获得,序号Y40593)为出发菌株,为具体实施例作进一步说明。
下列实施例中涉及到的培养基成分如下:
LB:10g/L蛋白胨,5g/L酵母提取物,10g/L NaCl。用于筛选转化质粒时,添加100μg/mL氨苄青霉素。
Se-Ura:0.77g/L CSM-Ura,6.9g/L YNB,0.5g/L葡萄糖,10ml乙醇。
YPE:20g/L胰蛋白胨,10g/L酵母提取物,0.5g/L葡萄糖,10ml乙醇。
YPD:20g/L胰蛋白胨,10g/L酵母提取物,20g/L葡萄糖。
SD-2×SCAA:6.9g/L YNB;1g/L BSA;13.62g/L Na2HPO4·12H2O;9.68g/LNaH2PO4·2H2O;190mg/L Arg;400mg/L Asp;1260mg/L Glu;130mg/L Gly;140mg/L His;290mg/L Ile;400mg/L Leu;440mg/L Lys;108mg/L Met;200mg/L Phe;220mg/L Thr;40mg/L Trp;52mg/L Tyr;380mg/L Val;20g/L葡萄糖。
固体培养基添加2%琼脂粉。
实施例1高效外泌蛋白的酿酒酵母工程菌的构建
酿酒酵母IMX581(基因型:MATa ura3-52 can1::cas9-natNT2 TRP1 LEU2 HIS3)是本实施例中的酵母基因工程菌出发菌。IMX581基因组中整合有CRISPR-Cas9系统中的Cas9蛋白表达基因盒。该出发菌株带有Ura营养型缺陷筛选标记。对该菌株进行基因敲除等遗传操作时,可将带有20bp gRNA识别序列以靶向目标基因的gRNA表达质粒(pROS10(可由EUROSCARF获得,序号P30787),带有Ura筛选标记)及其修复片段转化至菌体内,在相应的平板上筛选后,即可得到所需的阳性转化子。
1.1构建可转入表达质粒的酵母工程菌
带有POT1筛选标记的质粒CPOTud(Biotechnology and bioengineering,2012,109(5):1259-1268.)(裂殖酵母糖酵解途径中的关键酶磷酸丙糖异构酶)在本发明中用于重组蛋白的分泌表达,该质粒在敲除TPI1基因(SEQ ID NO:1)的酵母菌可稳定存在。因此,首先对出发菌株IMX581进行TPI1基因敲除,过程如下:
(1)以pROS10为模板,利用引物对tpi1P1和RP2,进行PCR扩增,得到靶向片段A(图1)。通过引物对vfP1和vfP2扩增出pROS10载体框架片段(图1),PCR反应体系和条件由表1和表2。
表1 PCR反应体系
表2 PCR条件
靶向片段A、靶向片段B延伸时间50s,载体框架片段延伸时间3min
利用引物对tpi1RS1,tpi11RS2,通过PCR反应进行自身互补扩增,得到80bp的修复片段A(tpi1-RS)(图2)。反应体系见表3,PCR条件见表4。
表3修复片段PCR反应体系
表4修复片段PCR条件
(2)通过琼脂糖凝胶电泳及切胶回收PCR产物,电泳图如图1所示。将得到的靶向片段A和载体框架以Gibson连接技术,进行带有TPI1基因gRNA靶向序列的pROS10-tpi1质粒的构建。连接体系如表5所示,配制好的连接液50℃孵育20min。转化至大肠杆菌DH5α感受态细胞。转化步骤如下:
a)连接液加入50μl感受态细胞,冰置30min。
b)42℃水浴75s,冰置5min。
c)加入500μl LB在37℃,100rpm复苏45min。
d)涂布于含有氨苄青霉素的LB平板,37℃过夜培养筛选。
第二天挑取单克隆接种于3ml带氨苄青霉素的LB液体培养基于37℃,200rpm培养12-16h,提取质粒,酶切及测序验证正确。
表5 Gibson连接体系
(3)将提取得到的TPI1靶向质粒(pROS10-tpi1)及tpi1修复片段A(tpi1-RS)一同转入酵母感受态细胞IMX581,具体流程为:
a)取50μl的感受态细胞,离心(1min,6000rpm)弃上清液。
b)按顺序加入表6系列化合物,混匀。
c)30℃孵育30min,42℃水浴45min。
d)涂布于Se-Ura固体平板。
e)30℃倒置培养3-4天,并回收转化子。
表6酵母转化混合体系
挑取转化子转移至YPE平板,30℃倒置培养2-3天,并挑取单克隆于25μlNaOH溶液(20mM),99℃破壁处理15min,使基因组渗透出细胞外。通过设计好的TPI1基因上下游匹配的引物对(tpi1Y1,tpi1Y2),以上述NaOH溶液作为模板,利用PCR确认染色体上的TPI1基因已被敲除。反应体系见表7,PCR条件见表8。扩增得到的验证片段A凝胶电泳条带见图3,并将切胶回收产物送至生工测序,确认TPI1敲除成功。
表7单克隆敲除验证PCR反应体系
表8单克隆敲除验证PCR条件
(4)挑取TPI1敲除成功的单克隆接种于3ml液体YPE培养基,培养4天(30℃,200rpm)进行pROS10-tpi1的质粒脱除,后划线于YPE固体培养基,30℃倒置培养2-3天。分别转移单克隆至Se-Ura固体平板、YPD固体平板和YPE固体平板上。30℃倒置培养2-3天,脱除敲除转入的辅助质粒pROS10-tpi1(在YPE平板生长,但不在Se-Ura平板和YPD平板生长的单克隆则为质粒脱除成功),得到的菌株命名为S1(即菌株IMX581ΔTPI1)。
1.2敲除SEC72基因
在1.1构建的菌株S1基础上,对SEC72基因(SEQ ID NO:2)进行敲除。
(1)以pROS10为模板,利用引物对sec72P1和RP2进行PCR扩增,得到靶向片段B(图1)。通过引物对vfP1和vfP2扩增出pROS10载体框架片段(图1),PCR反应体系和条件见表1和表2。
通过PCR反应进行自身互补扩增,得到80bp的修复片段B(sec72-RS)(图2)。反应体系见表3,PCR条件见表4。
(2)通过琼脂糖凝胶电泳及切胶回收PCR产物,电泳图如图1所示。将得到的靶向片段B和载体框架以Gibson连接技术,进行带有SEC72基因gRNA靶向序列的pROS10-sec72质粒的构建,连接体系如表5所示。详细操作过程同1.1(2),最终构建得到用于敲除SEC72的靶向质粒pROS10-sec72。
(3)将靶向质粒pROS10-sec72及SEC72修复片段B(sec72-RS)一同转入1.1中构建得到的酵母菌株S1感受态细胞,参照1.1步骤(3)(4)流程进行基因敲除。SEC72基因的敲除验证片段B的凝胶电泳条带见图3。酵母基工程菌S1ΔSEC72构建成功。
实施例2构建含不同信号肽的重组蛋白表达质粒
在进行重组蛋白表达时,可通过在目标蛋白前添加信号肽,以实现其在宿主细胞中的分泌表达。α-factor信号肽是酵母细胞中最为常用的信号肽。在本发明中,重组蛋白为α-淀粉酶,编码序列见SEQ ID NO.3。质粒pAlphaAmyCPOT(Biotechnology andbioengineering,2012,109(5):1259-1268.)为含有α-factor信号肽及α-淀粉酶基因的表达载体。在质粒pAlphaAmyCPOT的基础上,通过将α-factor信号肽(SEQ ID No.4)替换为NCW2信号肽(SEQ ID No.5)、MID2信号肽(SEQ ID No.6)、SWP1信号肽(SEQ ID No.7)、FET3信号肽(SEQ ID No.8)、FLO10信号肽(SEQ ID No.9),得到相应的质粒pNCW2AmyCPOT、pMID2AmyCPOT、pSWP1AmyCPOT、pFET3AmyCPOT、pFLO10AmyCPOT(图4)。详细构建过程如下:
(1)以质粒pAlphaAmyCPOT为模板,利用普通PCR扩增,利用引物对BP1和P2,CP1和P2,DP1和P2,EP1和P2以及FP1和P2进行PCR扩增,得到片段B、C、D、E、F。PCR体系和条件见表1和表2,延伸时间为50s。使用内切酶KpnI和NheI对PCR产物片段进行酶切,酶切体系见表8。同时对质粒pAlphaAmyCPOT进行酶切,以制备载体框架,酶切体系见表9。酶切体系37℃放置5-20min。使用胶回收试剂盒(美基)纯化回收得到酶切后的片段B~F,凝胶电泳、切胶回收获取酶切后的载体框架。载体框架酶切后凝胶电泳见图5。
表8信号肽-淀粉酶片段B~F酶切体系
表9载体pAlphaAmyCPOT酶切体系
(2)将酶切片段和载体框架进行连接,连接体系见表10。22℃孵育30min后,转化至大肠杆菌DH5α。对在含氨苄青霉素的LB平板上长出的阳性克隆进行培养,提取质粒,酶切及测序验证正确,确认质粒pNCW2AmyCPOT、pMID2AmyCPOT、pSWP1AmyCPOT、pFET3AmyCPOT、pFLO10AmyCPOT构建成功。
(3)采用常规的酵母转化法,将6种含不同信号肽的质粒pAlphaAmyCPOT、pNCW2AmyCPOT、pMID2AmyCPOT、pSWP1AmyCPOT、pFET3AmyCPOT、pFLO10AmyCPOT分别转化至酵母工程菌株S1和S1ΔSEC72中。转化流程同上,转化液涂布于YPD固体培养基,30℃培养2~3天,得到阳性克隆。最终共得到12株酵母菌株,分别为:pAlphaAmyCPOT/S1、pNCW2AmyCPOT/S1、pMID2AmyCPOT/S1、pSWP1AmyCPOT/S1、pFET3AmyCPOT/S1、pFLO10AmyCPOT/S1、pAlphaAmyCPOT/S1ΔSEC72、pNCW2AmyCPOT/S1ΔSEC72、pMID2AmyCPOT/S1ΔSEC72、pSWP1AmyCPOT/S1ΔSEC72、pFET3AmyCPOT/S1ΔSEC72、pFLO10AmyCPOT/S1ΔSEC72。
表10连接体系
上述过程所使用的全部引物序列见表11。
表11引物序列(下划线为gRNA序列)
实施例3利用敲除SEC72的酵母工程菌高效外泌重组蛋白
将实施例2构建得到的12株酿酒酵母工程菌接种于2.5ml SD-2×SCAA液体培养基中,在30℃,200rpm培养条件下发酵96h,得到上清液中即含有目标重组蛋白α-淀粉酶。将发酵液离心(3min,12000rpm)以分离上清,用于重组蛋白含量测定。测定方法依照α-淀粉酶试剂盒(Megazyme K-CERA)操作说明进行。同时采用以米曲霉来源淀粉酶(Sigma-Aldrich)作淀粉酶活力标准曲线并进行换算。质量-酶活力换算单位为69.6U/mg。最终淀粉酶产量结果见图6。由结果可知,在SEC72敲除后的酵母工程菌中,不同信号肽介导下的重组蛋白分泌产量均有了较大提升。其中,菌株pNCW2AmyCPOT/S1ΔSEC72(对应NCW2信号肽),产量达425mg/L,是未敲除SEC72对照菌的2.5倍。说明本发明构建得到的酵母工程菌株具有高效分泌重组蛋白的能力,靶点SEC72对于不同信号肽具有普适性。在分泌生产重组蛋白上,具有较好的应用潜力。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
序列表
<110> 华南理工大学
<120> 一株高效外泌蛋白的酵母工程菌及其构建方法和应用
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1377
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> TPI1基因
<400> 1
atgggtaaag agaagtctca cattaacgtt gtcgttatcg gtcatgtcga ttctggtaag 60
tctaccacta ccggtcattt gatttacaag tgtggtggta ttgacaagag aaccatcgaa 120
aagttcgaaa aggaagccgc tgaattaggt aagggttctt tcaagtacgc ttgggttttg 180
gacaagttaa aggctgaaag agaaagaggt atcactatcg atattgcttt gtggaagttc 240
gaaactccaa agtaccaagt taccgttatt gatgctccag gtcacagaga tttcatcaag 300
aacatgatta ctggtacttc tcaagctgac tgtgctatct tgattattgc tggtggtgtc 360
ggtgaattcg aagccggtat ctctaaggat ggtcaaacca gagaacacgc tttgttggct 420
ttcaccttgg gtgttagaca attgattgtt gctgtcaaca agatggactc cgtcaaatgg 480
gacgaatcca gattccaaga aattgtcaag gaaacctcca actttatcaa gaaggttggt 540
tacaacccaa agactgttcc attcgtccca atctctggtt ggaacggtga caacatgatt 600
gaagctacca ccaacgctcc atggtacaag ggttgggaaa aggaaaccaa ggccggtgtc 660
gtcaagggta agactttgtt ggaagccatt gacgccattg aacaaccatc tagaccaact 720
gacaagccat tgagattgcc attgcaagat gtttacaaga ttggtggtat tggtactgtg 780
ccagtcggta gagttgaaac cggtgtcatc aagccaggta tggttgttac ttttgcccca 840
gctggtgtta ccactgaagt caagtccgtt gaaatgcatc acgaacaatt ggaacaaggt 900
gttccaggtg acaacgttgg tttcaacgtc aagaacgttt ccgttaagga aatcagaaga 960
ggtaacgtct gtggtgacgc taagaacgat ccaccaaagg gttgcgcttc tttcaacgct 1020
accgtcattg ttttgaacca tccaggtcaa atctctgctg gttactctcc agttttggat 1080
tgtcacactg ctcacattgc ttgtagattc gacgaattgt tggaaaagaa cgacagaaga 1140
tctggtaaga agttggaaga ccatccaaag ttcttgaagt ccggtgacgc tgctttggtc 1200
aagttcgttc catctaagcc aatgtgtgtt gaagctttca gtgaataccc accattaggt 1260
agattcgctg tcagagacat gagacaaact gtcgctgtcg gtgttatcaa gtctgttgac 1320
aagactgaaa aggccgctaa ggttaccaag gctgctcaaa aggctgctaa gaaataa 1377
<210> 2
<211> 582
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> SEC72基因
<400> 2
atggttaccc ttgaatacaa tgcaaacagt aaactgatca ctgcgagtga tgctgttgtt 60
gcactatcta ccgaaactaa tatcgatcaa ataaatgttc tcactacatc tttgattgga 120
gaaaccaacc caaattttac accacaaccg aatgaagctc taagcaaaat gatcaagggt 180
ttatttgaaa gtggtatgaa gaatttacaa caaaaaaaat tgaatgaggc attgaagaat 240
gtttctttag caatcgaaat ggcacaaaga aaaagagcgc cttgggaagc ttttgctatt 300
cagctaccag agctacactt tatgcttcgt agtaaaatag atttatgttt aatactcgga 360
aagcatttag aggcgttgca agacttggat ttcttacttg gtacgggact tatccaacca 420
gacgtatttg tcaggaaggc ggactgtttg ctaaaattga gacagtggga agaggctagg 480
gcaacatgcg agagaggttt agctttagcc ccagaggata tgaaacttag agccctttta 540
atagaaactg caagaaatct ggccgaatat aacggtgaat aa 582
<210> 3
<211> 1437
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> α-淀粉酶
<400> 3
gcaacgcctg cggactggcg atcgcaatcc atttatttcc ttctcacgga tcgatttgca 60
aggacggatg ggtcgacgac tgcgacttgt aatactgcgg atcggaaata ctgtggtgga 120
acatggcagg gcatcatcga caagttggac tatatccagg gaatgggctt cacagccatc 180
tggatcaccc ccgttacagc ccagctgccc cagaccaccg catatggaga tgcctaccat 240
ggctactggc agcaggatat atactctctg aacgaaaact acggcactgc agatgacttg 300
aaggcgctct cttcggccct tcatgagagg gggatgtatc ttatggtcga tgtggttgct 360
aaccatatgg gctatgatgg agcgggtagc tcagtcgatt acagtgtgtt taaaccgttc 420
agttcccaag actacttcca cccgttctgt ctcattcaaa actatgaaga tcagactcag 480
gttgaggatt gctggctagg agataacact gtctccttgc ctgatctcga taccaccaag 540
gatgtggtca agaatgaatg gtacgactgg gtgggatcat tggtatcgaa ctactccatt 600
gacggcctcc gtatcgacac agtaaaacac gtccagaagg acttctggcc cgggtacaac 660
aaagccgcag gcgtgtactg tatcggcgag gtgctcgacg gtgatccggc ctacacttgt 720
ccctaccaga acgtcatgga cggcgtactg aactatccca tttactatcc actcctcaac 780
gccttcaagt caacctccgg cagcatggac gacctctaca acatgatcaa caccgtcaaa 840
tccgactgtc cagactcaac actcctgggc acattcgtcg agaaccacga caacccacgg 900
ttcgcttctt acaccaacga catagccctc gccaagaacg tcgcagcatt catcatcctc 960
aacgacggaa tccccatcat ctacgccggc caagaacagc actacgccgg cggaaacgac 1020
cccgcgaacc gcgaagcaac ctggctctcg ggctacccga ccgacagcga gctgtacaag 1080
ttaattgcct ccgcgaacgc aatccggaac tatgccatta gcaaagatac aggattcgtg 1140
acctacaaga actggcccat ctacaaagac gacacaacga tcgccatgcg caagggcaca 1200
gatgggtcgc agatcgtgac tatcttgtcc aacaagggtg cttcgggtga ttcgtatacc 1260
ctctccttga gtggtgcggg ttacacagcc ggccagcaat tgacggaggt cattggctgc 1320
acgaccgtga cggttggttc ggatggaaat gtgcctgttc ctatggcagg tgggctacct 1380
agggtattgt atccgactga gaagttggca ggtagcaaga tctgtagtag ctcgtga 1437
<210> 4
<211> 89
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<223> α-factor信号肽
<400> 4
Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser
1 5 10 15
Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln
20 25 30
Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe
35 40 45
Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu
50 55 60
Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val
65 70 75 80
Ser Leu Glu Lys Arg Glu Ala Glu Ala
85
<210> 5
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<223> NCW2信号肽
<400> 5
Met Lys Ala Cys Ser Ile Leu Phe Thr Thr Leu Ile Thr Leu Ala Ala
1 5 10 15
Ala
<210> 6
<211> 25
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<223> MID2信号肽
<400> 6
Met Leu Ser Phe Thr Thr Lys Asn Ser Phe Arg Leu Leu Leu Leu Ile
1 5 10 15
Leu Ser Cys Ile Ser Thr Ile Arg Ala
20 25
<210> 7
<211> 19
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<223> SWP1信号肽
<400> 7
Met Gln Phe Phe Lys Thr Leu Ala Ala Leu Val Ser Cys Ile Ser Phe
1 5 10 15
Val Leu Ala
<210> 8
<211> 21
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<223> FET3信号肽
<400> 8
Met Thr Asn Ala Leu Leu Ser Ile Ala Val Leu Leu Phe Ser Met Leu
1 5 10 15
Ser Leu Ala Gln Ala
20
<210> 9
<211> 24
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<223> FLO10信号肽
<400> 9
Met Pro Val Ala Ala Arg Tyr Ile Phe Leu Thr Gly Leu Phe Leu Leu
1 5 10 15
Ser Val Ala Asn Val Ala Leu Gly
20
Claims (10)
1.一株酵母基因工程菌,其特征在于:是敲除酵母菌株中的SEC72基因后得到;
所述的酵母基因工程菌还含有携带信号肽的重组蛋白分泌表达质粒。
2.根据权利要求1所述的酵母基因工程菌,其特征在于:所述SEC72基因的序列如SEQID NO:2所示。
3.根据权利要求1所述的酵母基因工程菌,其特征在于:所述的酵母菌株为酿酒酵母IMX581、CEN.PK2-1C、CEN.PK2-1D、BY4741、BY4742、CEN.PK530.1C、CEN.PK 113.5D、B184M。
4.根据权利要求1所述的酵母基因工程菌,其特征在于:所述信号肽是NCW2、MID2、SWP1、FET3、FLO10或α-factor中的一种。
5.根据权利要求1所述的酵母基因工程菌,其特征在于:所述的重组蛋白是α-淀粉酶、脂肪酶、β-淀粉酶、蛋白酶、乳糖酶、α-葡萄糖苷酶、葡糖异构酶、转化酶、纤维素酶、纤维二糖酶、人血清白蛋白、病毒表面抗原、人胰岛素、人粒细胞集落刺激因子、人血管抑制素、抗体。
6.根据权利要求1所述的酵母基因工程菌,其特征在于:所述的重组蛋白分泌表达质粒带有POT1筛选标记。
7.根据权利要求6所述的酵母基因工程菌,其特征在于:还敲除了酵母菌株中的TPI1基因。
8.根据权利要求7所述的酵母基因工程菌,其特征在于:所述TPI1基因的序列如SEQ IDNO:1所示。
9.权利要求1-8任一项所述酵母基因工程菌的构建方法,其特征在于包括以下步骤:
敲除酵母菌株上的SEC72基因,构建携带信号肽的重组蛋白分泌表达质粒,将携带信号肽的重组蛋白分泌表达质粒转化至敲除SEC72基因的酵母菌株中,得到所述酵母基因工程菌。
10.权利要求1-8任一项所述的酵母基因工程菌在表达重组蛋白中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210642012.9A CN115141763B (zh) | 2022-06-08 | 2022-06-08 | 一株高效外泌蛋白的酵母工程菌及其构建方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210642012.9A CN115141763B (zh) | 2022-06-08 | 2022-06-08 | 一株高效外泌蛋白的酵母工程菌及其构建方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115141763A true CN115141763A (zh) | 2022-10-04 |
CN115141763B CN115141763B (zh) | 2023-11-17 |
Family
ID=83408392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210642012.9A Active CN115141763B (zh) | 2022-06-08 | 2022-06-08 | 一株高效外泌蛋白的酵母工程菌及其构建方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115141763B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115820714A (zh) * | 2022-12-15 | 2023-03-21 | 浙江大学杭州国际科创中心 | 一种提高多聚半乳糖醛酸酶分泌的基因工程菌及其构建方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228590B1 (en) * | 1998-03-23 | 2001-05-08 | Genentech, Inc. | Method of selection for genes encoding secreted and transmembrane proteins |
CN112166181A (zh) * | 2018-05-17 | 2021-01-01 | 保尔特纺织品公司 | 用于改善重组蛋白分泌的sec经修饰菌株 |
-
2022
- 2022-06-08 CN CN202210642012.9A patent/CN115141763B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228590B1 (en) * | 1998-03-23 | 2001-05-08 | Genentech, Inc. | Method of selection for genes encoding secreted and transmembrane proteins |
CN112166181A (zh) * | 2018-05-17 | 2021-01-01 | 保尔特纺织品公司 | 用于改善重组蛋白分泌的sec经修饰菌株 |
Non-Patent Citations (3)
Title |
---|
JIAYUAN SHENG ET AL: "Systematic Optimization of Protein Secretory Pathways in Saccharomyces cerevisiae to Increase Expression of Hepatitis B Small Antigen", FRONTIERS IN MICROBIOLOGY, vol. 08, pages 1 - 10 * |
ZIHE LIU ET AL: "Different expression systems for production of recombinant proteins in Saccharomyces cerevisiae" * |
ZIHE LIU ET AL: "Different expression systems for production of recombinant proteins in Saccharomyces cerevisiae", BIOTECHNOL BIOENG, vol. 109, no. 5, pages 2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115820714A (zh) * | 2022-12-15 | 2023-03-21 | 浙江大学杭州国际科创中心 | 一种提高多聚半乳糖醛酸酶分泌的基因工程菌及其构建方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115141763B (zh) | 2023-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106978360B (zh) | 一株高产纤维素酶里氏木霉重组菌株及其应用 | |
WO2016169306A1 (zh) | 糖基化改造提高脂肪酶表达的方法、突变酶及其应用 | |
CN108034667B (zh) | 一种红色红曲霉α-淀粉酶基因、其制备方法及应用 | |
CN107574173B (zh) | 一种重组质粒及其用于构建红曲色素高产菌株的方法 | |
CN108085308B (zh) | 一种能提高耐热脂肪酶产量的重组工程菌及其构建方法和应用 | |
CN110117601B (zh) | 灰树花葡聚糖合成酶、其编码基因及应用 | |
CN112522125B (zh) | 一种透明质酸酶工程菌及其构建方法与应用 | |
CN115011616B (zh) | 一种乙醛脱氢酶基因rkaldh及其应用 | |
CN113604472B (zh) | 一种应用于里氏木霉的CRISPR/Cas基因编辑系统 | |
Chen et al. | Heterologous expression and characterization of Penicillium citrinum nuclease P1 in Aspergillus niger and its application in the production of nucleotides | |
CN115141763B (zh) | 一株高效外泌蛋白的酵母工程菌及其构建方法和应用 | |
CN110938614A (zh) | 高活性β-半乳糖苷酶、高通量筛选该酶的质粒及其制备方法 | |
US11613745B2 (en) | Recombinant oxalate decarboxylase expressed in filamentous fungi | |
WO2022095221A1 (zh) | 多肽标签、高度可溶性的重组腈水解酶及其在医药化学品合成中的应用 | |
CN116286750A (zh) | 一种β-葡萄糖苷酶、编码基因、重组载体、工程菌及应用 | |
CN115948265A (zh) | 一种马克斯克鲁维单倍体酵母及其构建方法与应用 | |
CN113930348B (zh) | 一种以葡萄糖为底物生物合成甘草次酸的解脂耶氏酵母工程菌株、构建及其应用 | |
CN108949579B (zh) | 嗜热子囊菌基因表达系统 | |
CN114644987A (zh) | 一种提高l-苹果酸生产水平和发酵强度的黑曲霉菌株、方法及应用 | |
CN106119137B (zh) | 一种改善丝状真菌蛋白分泌能力的方法 | |
CN109371053B (zh) | 一种红曲色素产生菌株构建方法 | |
CN114540397B (zh) | 增强调控蛋白表达以提高谷氨酰胺转氨酶发酵水平的方法 | |
CN111334523A (zh) | 一种大尺度dna的体内多轮迭代组装方法 | |
CN117343950B (zh) | 一种提高里氏木霉表达外源蛋白表达水平的方法 | |
WO2024114637A1 (zh) | 生产阿卡波糖的工程菌及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |